Targeting RECQL4 in hepatocellular carcinoma: from prognosis to therapeutic potential.

ABSTRACT:

Objective

The aim of this study is to assess the clinical utility of RecQ Like Helicase 4 (RECQL4) as a prognostic marker in hepatocellular carcinoma (HCC) and investigate its associations with various biological processes, angiogenesis-related factors, immune cell infiltration, immune checkpoints, and drug sensitivity.

Methods

RECQL4 expression was analyzed across a range of cancer types utilizing data from the TCGA database. Disparities in RECQL4 expression levels between normal and malignant tissues were evaluated, alongside an analysis of progression-free interval (PFI), disease-specific survival (DSS), and overall survival (OS) curves. Exploration of pertinent pathways, immune cell infiltration, single-cell RNA-seq data, and drug sensitivity was conducted employing The

SUBMITTER: Li Y 

PROVIDER: S-EPMC11863661 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature